Health-related quality of life (HRQoL) evaluation in the REGOMA trial: A randomized, phase II clinical trial analyzing regorafenib activity in relapsed glioblastoma patients

被引：0
作者：
Lombardi, G. [1 ]
Del Bianco, P. [2 ]
Brandes, A. A. [3 ]
Eoli, M. [4 ]
Ruda, R. [5 ,6 ]
Ibrahim, T. [7 ]
Lolli, I. R. [8 ]
Pace, A. [9 ]
Daniele, B. [10 ]
Pasqualetti, F. [11 ]
Rizzato, S. [12 ]
Bergo, E. [1 ]
Caccese, M. [1 ]
Padovan, M. [1 ]
Soffietti, R. [5 ,6 ]
De Salvo, G. L. [2 ]
Zagonel, V. [1 ]
机构：
[1] IOV IRCCS, Veneto Inst Oncol, Dept Oncol, Oncol 1, Padua, Italy
[2] IOV IRCCS, Veneto Inst Oncol, Clin Res Unit, Padua, Italy
[3] AUSL IRCCS Sci Neurol, Dept Med Oncol, Bologna, Italy
[4] Besta Inst, Mol Neurooncol Unit, Milan, Italy
[5] Univ Turin, Dept Neurooncol, Turin, Italy
[6] City Hlth & Sci Hosp, Turin, Italy
[7] IRST Ist Sci Romagnolo Studio & Cura Tumori IRCCS, Med Oncol Unit, Meldola, Forli Cesena, Italy
[8] IRCCS Saverio de Bellis, Med Oncol Unit, Bari, Italy
[9] Regina Elena Canc Inst IRCCS, Neuroncol Unit, Rome, Italy
[10] AOG Rummo, Med Oncol Unit, Benevento, Italy
[11] Azienda Osped Univ, Radiotherapy Unit, Pisa, Italy
[12] Azienda Sanit Univ Integrata Udine, Dept Oncol, Udine, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
394O
引用
收藏
页数：1
相关论文
共 50 条
  • [21] UPDATED RESULTS OF REGOMA: A RANDOMIZED, MULTICENTER, CONTROLLED OPEN-LABEL PHASE II CLINICAL TRIAL EVALUATING REGORAFENIB IN RELAPSED GLIOBLASTOMA <GBM> PATIENTS <PTS>
    Lombardi, G.
    de Salvo, G.
    Ruda, R.
    Franceschi, E.
    Eoli, M.
    Faedi, M.
    Pace, A.
    Lolli, I.
    Rizzato, S.
    Germano, D.
    Pasqualetti, F.
    Farina, M.
    Magni, G.
    Bellu, L.
    Caccese, M.
    Pambuku, A.
    Bergo, E.
    Indraccolo, S.
    Gardiman, M.
    Soffietti, R.
    Zagonel, V.
    NEURO-ONCOLOGY, 2018, 20 : 219 - 219
  • [22] Prospective Evaluation of Health-Related Quality of Life and Neurocognitive Status in Patients With Glioblastoma Multiforme Treated on a Phase II Trial of Hypofractionated Radiation Therapy With Temozolomide
    Reddy, K.
    Gaspar, L. E.
    Kavanagh, B. D.
    Waziri, A.
    Chen, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S269 - S269
  • [23] Impact of bevacizumab added to temozolomide-chemoradiation on time to health-related quality of life deterioration in unresectable glioblastoma: Results of a phase II randomized clinical trial
    Bonnetain, Franck
    Dabakuyo, Tienhan Sandrine
    Pozet, Astrid
    Feuvret, Loic
    Taillandier, Luc
    Frappaz, Didier
    Taillia, Herve
    Schott, Roland
    Honnorat, Jerome
    Fabbro, Michel
    Tennevet, Isabelle
    Ghiringhelli, Francois
    Campello, Chantal
    Castera, Daniel
    Frenay, Marc
    Dalban, Cecile
    Skrzypski, Jeremy
    Chinot, Olivier L.
    Chauffert, Bruno
    Anota, Amelie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma
    Kathryn M. Field
    Madeleine T. King
    John Simes
    David Espinoza
    Elizabeth H. Barnes
    Kate Sawkins
    Mark A. Rosenthal
    Lawrence Cher
    Elizabeth Hovey
    Helen Wheeler
    Anna K. Nowak
    Journal of Neuro-Oncology, 2017, 133 : 623 - 631
  • [25] Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma
    Field, Kathryn M.
    King, Madeleine T.
    Simes, John
    Espinoza, David
    Barnes, Elizabeth H.
    Sawkins, Kate
    Rosenthal, Mark A.
    Cher, Lawrence
    Hovey, Elizabeth
    Wheeler, Helen
    Nowak, Anna K.
    JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (03) : 623 - 631
  • [26] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL
    Walbert, T.
    Lavy-Shahaf, G.
    NEURO-ONCOLOGY, 2018, 20 : 242 - 242
  • [27] HEALTH-RELATED QUALITY OF LIFE (HRQOL) ANALYSES IN THE AVAGLIO STUDY, A RANDOMIZED, PLACEBO-CONTROLLED PHASE III TRIAL OF BEVACIZUMAB, TEMOZOLOMIDE AND RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA
    Taphoorn, Martin J. B.
    Henriksson, Roger
    Bottomley, Andrew
    Cloughesy, Timothy
    Wick, Wolfgang
    Mason, Warren
    Saran, Frank
    Nishikawa, Ryo
    Ravelo, Arliene
    Hilton, Magalie
    Chinot, Olivier L.
    NEURO-ONCOLOGY, 2013, 15 : 232 - 232
  • [28] EFFECTS OF TUMOR TREATING FIELDS ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA: AN EXPLORATORY ANALYSIS OF THE EF-14 RANDOMIZED PHASE III TRIAL
    Walbert, Tobias
    Lavy-Shahaf, Gitit
    NEURO-ONCOLOGY, 2018, 20 : 214 - 214
  • [29] Effects of Alefacept on Health-Related Quality of Life in Patients with PsoriasisResults from a Randomized, Placebo-Controlled Phase II Trial
    Charles N. Ellis
    Margaret M. Mordin
    Ellen Y. Adler
    American Journal of Clinical Dermatology, 2003, 4 : 131 - 139
  • [30] Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin
    Diana Rofail
    Antoine Regnault
    Stéphanie le Scouiller
    Carmen Galani Berardo
    Daniel Umbricht
    Ray Fitzpatrick
    Quality of Life Research, 2016, 25 : 201 - 211
12345